We found that SGLT2 inhibitors decreased the incidence of sepsis (RR 0.34, 95% CI 0.28, 0.40, P < 0.0001, I2 = 0%), UTI (RR 0.54, 95% CI 0.40, 0.72, P < 0.0001, I2 = 0%), and kidney injury (RR 0.72, 95% CI 0.56, 0.93, P = 0.0104, I2 = 0%). Here, SLC5A2 is linked to injury.